Mercedes-Benz to Release Luxury Electric Van in China 
Chipotle Scraps Farmesa Fresh Eatery spinoff, Ghost Kitchen Cease Operations 
New Study Reveals Coke, Pepsi, and Nestle as Top Plastic Polluters 
Mercedes Launches 2025 G-Class Electric with Four Motors and Revolutionary Tank Turns 
Visa's Q2 Earnings Surpass Expectations, Fueled by Consumer Spending 
Supreme Court appears open to Starbucks’ claims in labor-organizing case 
PUMA and Scuderia Ferrari HP Unveil Miami Limited Edition Collection 
Tesla Cybertruck Hits 1,000-Unit Weekly Production Amid Q1 Financial Shortfalls 
Toyota Teams with Tencent, Nissan Joins Forces with Baidu in China AI Drive 
Asahi Kasei to Build EV Battery Plant in Canada to Supply Key Parts to Honda Motor 
If plastic manufacturing goes up 10%, plastic pollution goes up 10% – and we’re set for a huge surge in production 
IBM Acquires HashiCorp, Giving Its Hybrid-Cloud Business a Boost 
TikTok Vows to Fight US Ban After Biden Signed Bill 
GS25 Launches Limited-Edition Makgeolli ‘Seoul Silver’ in Korea 
Extraordinary Vietnam fraud case exposes the inherent vulnerabilities of banks 
Ferrari F1 Announces Multi-Year Partnership with HP as Title Sponsor 
US SEC Set to Reject Spot Ether ETFs in May Amid Regulatory Hurdles 
TEL AVIV, Israel, Jan. 28, 2016 -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced upcoming corporate presentations at the BIO CEO and Investor Conference and the 1st Annual Neuroscience BioPartnering & Investment Forum.
| BIO CEO & Investor Conference | |
| Date: | Monday, February 8 |
| Time: | 8:30am ET |
| Location: | Waldorf Astoria, New York, NY |
| 1st Annual Neuroscience BioPartnering & Investment Forum | |
| Date: | Tuesday, February 23 |
| Time: | 4:10pm ET |
| Location: | The New York Academy of Sciences, New York, NY |
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 [email protected] Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 [email protected] Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 [email protected]
